120
Participants
Start Date
December 20, 2018
Primary Completion Date
May 7, 2024
Study Completion Date
May 7, 2024
TEW-7197
"Vactosertib will be administered orally without regard to meals for 5 days per week (5D/W) at the same time in the morning (QD), at the same time in the morning and evening (BID) approximately 12 hours apart.~Pembrolizumab will be administered as a dose of 200 mg using a 30-minute IV infusion. Sites should make every effort to target infusion timing to be as close to 30 minutes as possible."
National Cancer Center, Goyang
Seoul National University Bundang Hospital, Seongnam
Samsung Medical Center, Seoul
Yeonsei University Hospital, Seoul
Asan Medical Center, Seoul
Lead Sponsor
Merck Sharp & Dohme LLC
INDUSTRY
MedPacto, Inc.
INDUSTRY